{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:53:56Z","timestamp":1793058836199,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.neurol.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T09:36:22Z","timestamp":1667468182000},"page":"999-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-4289","authenticated-orcid":false,"given":"N.","family":"Villain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3713-227X","authenticated-orcid":false,"given":"V.","family":"Planche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2022.08.002_bib441","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurol.2022.06.012","article-title":"High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects","author":"Villain","year":"2022","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2022.08.002_bib0225","unstructured":"Aduhelm: Pending EC decision | European Medicines Agency n.d. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/aduhelm (accessed January 18, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0230","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.phrs.2021.105754","article-title":"Aducanumab for Alzheimer's disease: a regulatory perspective","volume":"171","author":"Nistic\u00f2","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.neurol.2022.08.002_bib0235","unstructured":"Update on the Phase 4 Confirmatory Study of ADUHELM\u00ae | Biogen n.d. https:\/\/investors.biogen.com\/news-releases\/news-release-details\/update-phase-4-confirmatory-study-aduhelmr (accessed January 17, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0240","unstructured":"Autorisation de mise sur le march\u00e9 pour les m\u00e9dicaments - ANSM n.d. https:\/\/ansm.sante.fr\/page\/autorisation-de-mise-sur-le-marche-pour-les-medicaments (accessed January 25, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0245","unstructured":"EISAI statement on the Centers for Medicare and Medicaid services\u2019 national coverage determination with coverage with evidence development for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease | News Release: 2022 | Eisai Co., Ltd. n.d. https:\/\/ww.eisai.com\/news\/2022\/news202226.html (accessed April 25, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0250","unstructured":"M\u00e9dicaments innovants\u00a0: consolider le mod\u00e8le fran\u00e7ais d\u2019acc\u00e8s pr\u00e9coce - S\u00e9nat n.d. https:\/\/ww.senat.fr\/notice-rapport\/2017\/r17-569-notice.html (accessed January 25, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0255","unstructured":"Innovation Sant\u00e9 2030 - Minist\u00e8re des Solidarit\u00e9s et de la Sant\u00e9 n.d. https:\/\/solidarites-sante.gouv.fr\/actualites\/presse\/dossiers-de-presse\/article\/innovation-sante-2030 (accessed January 25, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0260","unstructured":"Migraines s\u00e9v\u00e8res\u00a0: ce traitement innovant dont la France ne veut pas | Slate.fr n.d. http:\/\/www.slate.fr\/story\/205520\/migraines-severes-traitement-innovant-anticorps-monoclonaux-maladie-douleurs (accessed January 25, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0265","unstructured":"M\u00e9dicaments\u00a0: ils vont \u00e0 l\u2019\u00e9tranger pour se faire soigner - Le Parisien n.d. https:\/\/www.leparisien.fr\/archives\/je-ne-me-sens-pas-comme-une-delinquante-05-04-2016-5686925.php (accessed January 25, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0270","doi-asserted-by":"crossref","first-page":"398","DOI":"10.14283\/jpad.2021.41","article-title":"Aducanumab: appropriate use recommendations","volume":"8","author":"Cummings","year":"2021","journal-title":"J Prev Alzheimer's Dis"},{"key":"10.1016\/j.neurol.2022.08.002_bib0275","doi-asserted-by":"crossref","first-page":"221","DOI":"10.14283\/jpad.2022.34","article-title":"Aducanumab: appropriate use recommendations update","volume":"9","author":"Cummings","year":"2022","journal-title":"J Prev Alzheimer's Dis"},{"key":"10.1016\/j.neurol.2022.08.002_bib0280","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/archneurol.2011.70","article-title":"Amyloid-dependent and amyloid-independent stages of Alzheimer disease","volume":"68","author":"Hyman","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2022.08.002_bib0285","first-page":"209","article-title":"Standardisation et \u00e9talonnage fran\u00e7ais du \u201cMini Mental State\u201d (MMS) version GR\u00c9CO. [French standardization and range for the GRECO version of the \u201cMini Mental State\u201d (MMS).]","volume":"13","author":"Kalafat","year":"2003","journal-title":"Rev Neuropsychol"},{"key":"10.1016\/j.neurol.2022.08.002_bib0290","article-title":"Influence of education level on MMSE and MoCA scores of elderly inpatients","author":"Wu","year":"2021","journal-title":"Appl Neuropsychol Adult"},{"key":"10.1016\/j.neurol.2022.08.002_bib0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/09084282.2011.643962","article-title":"Is the Folstein's Mini-Mental test an aphasia test?","volume":"19","author":"Vigliecca","year":"2012","journal-title":"Appl Neuropsychol Adult"},{"key":"10.1016\/j.neurol.2022.08.002_bib0300","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jalz.2018.03.005","article-title":"Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimer's Dement"},{"key":"10.1016\/j.neurol.2022.08.002_bib0305","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","article-title":"Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group","volume":"20","author":"Dubois","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.08.002_bib0310","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","article-title":"Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration","volume":"26","author":"Thijssen","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2022.08.002_bib0315","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"key":"10.1016\/j.neurol.2022.08.002_bib0320","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.neurol.2022.08.002_bib443","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: the amyloid hypothesis revised","volume":"23","author":"Frisoni","year":"2022","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.neurol.2022.08.002_bib0325","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/brain\/awab099","article-title":"Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease","volume":"144","author":"Spina","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.neurol.2022.08.002_bib0330","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ppar\/23.2.3","article-title":"Life expectancy, health, and functioning among the 85-Plus population in Europe and the United States","volume":"23","author":"Crimmins","year":"2013","journal-title":"Public Policy Aging Rep"},{"key":"10.1016\/j.neurol.2022.08.002_bib0335","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3233\/JAD-180675","article-title":"Clinical evaluation of amyloid-related imaging abnormalities in Bapineuzumab Phase III studies","volume":"66","author":"Brashear","year":"2018","journal-title":"J Alzheimer's Dis"},{"key":"10.1016\/j.neurol.2022.08.002_bib0340","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease \u2014 one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2022.08.002_bib0345","doi-asserted-by":"crossref","first-page":"211","DOI":"10.14283\/jpad.2022.21","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer's Disease treated with anti-amyloid beta therapy","volume":"2","author":"Barakos","year":"2022","journal-title":"J Prev Alzheimer's Dis"},{"key":"10.1016\/j.neurol.2022.08.002_bib0350","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S1474-4422(21)00213-1","article-title":"Off-label use of aducanumab for cerebral amyloid angiopathy","volume":"20","author":"Greenberg","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2022.08.002_bib0355","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/STROKEAHA.121.036873","article-title":"Vessels sing their ARIAs: the role of vascular amyloid in the age of aducanumab","volume":"53","author":"Sveikata","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.neurol.2022.08.002_bib0360","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2021.15286","article-title":"Representativeness of participants eligible to be enrolled in clinical trials of aducanumab for Alzheimer Disease compared with medicare beneficiaries with Alzheimer Disease and mild cognitive impairment","volume":"326","author":"Anderson","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2022.08.002_bib0365","doi-asserted-by":"crossref","first-page":"e0195324","DOI":"10.1371\/journal.pone.0195324","article-title":"Serious hemorrhages after ischemic stroke or TIA\u2013Incidence, mortality, and predictors","volume":"13","author":"\u00d6gren","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2022.08.002_bib0370","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1161\/01.STR.0000177480.62341.6b","article-title":"Major risk factors for intracerebral hemorrhage in the young are modifiable","volume":"36","author":"Feldmann","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.neurol.2022.08.002_bib0375","series-title":"The Boston criteria version 2. 0 for cerebral amyloid angiopathy\u00a0: a multicentre, retrospective, MRI\u2013neuropathology diagnostic accuracy study","first-page":"21","author":"Charidimou","year":"2022"},{"issue":"1","key":"10.1016\/j.neurol.2022.08.002_bib442","first-page":"106","article-title":"Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis","volume":"87","author":"Arrighi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2022.08.002_bib0380","series-title":"Maladie d\u2019Alzheimer\u00a0: quels impacts\u00a0? Rencontres Francoph. sur la Mal. d\u2019Alzheimer les Syndr. Apparent., Marseille","author":"Dufouil","year":"2021"},{"key":"10.1016\/j.neurol.2022.08.002_bib0385","series-title":"Global estimates on the number of persons across the Alzheimer's disease continuum","first-page":"1","author":"Gustavsson","year":"2022"},{"key":"10.1016\/j.neurol.2022.08.002_bib0390","first-page":"8","article-title":"\u201cReal-world\u201d eligibility for aducanumab depends on clinical setting and patients\u2019 journey","author":"Padovani","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.neurol.2022.08.002_bib0395","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1111\/jgs.17390","article-title":"Real world\u201d eligibility for aducanumab","volume":"69","author":"Canevelli","year":"2021","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.neurol.2022.08.002_bib0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bmjopen-2019-029663","article-title":"How many patients are eligible for disease-modifying treatment in Alzheimer's disease?. A French national observational study over 5 years","volume":"9","author":"Epelbaum","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurol.2022.08.002_bib0405","unstructured":"Maladie d\u2019Alzheimer et autres d\u00e9mences n.d. https:\/\/www.santepubliquefrance.fr\/maladies-et-traumatismes\/maladies-neurodegeneratives\/maladie-d-alzheimer-et-autres-demences\/donnees\/#tabs (accessed January 27, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0410","unstructured":"Observatoire Cap Retraite. La France face \u00e0 la prise en charge de la maladie d\u2019Alzheimer 2015. https:\/\/www.capretraite.fr\/wp-content\/uploads\/2016\/04\/synthese-observatoire-alzheimer.pdf (accessed January 27, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0415","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.lpm.2017.10.029","article-title":"Vers une strat\u00e9gie nationale de diagnostic des troubles cognitifs. Approche commune du Coll\u00e8ge de m\u00e9decine g\u00e9n\u00e9rale et des sp\u00e9cialistes des troubles neurocognitifs","volume":"47","author":"Krolak-Salmon","year":"2018","journal-title":"Press Med"},{"key":"10.1016\/j.neurol.2022.08.002_bib0420","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer's Dement J Alzheimer's Assoc"},{"key":"10.1016\/j.neurol.2022.08.002_bib0425","first-page":"02142","article-title":"Amyloid-related imaging abnormalities in 2 Phase 3 Studies evaluating aducanumab in patients with early Alzheimer Disease","author":"Salloway","year":"2021","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2022.08.002_bib0430","unstructured":"Two-thirds of neurologists expect to start some patients on Aduhelm next year: survey - Clinical Daily News - McKnight's Long-Term Care News n.d. https:\/\/www.mcknights.com\/news\/clinical-news\/two-thirds-of-neurologists-expect-to-start-some-patients-on-aduhelm-next-year-survey\/ (accessed January 26, 2022)."},{"key":"10.1016\/j.neurol.2022.08.002_bib0435","first-page":"9","article-title":"Key components of shared decision making models: a systematic review","author":"Bomhof-Roordink","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurol.2022.08.002_bib0440","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1212\/WNL.0000000000013053","article-title":"Decisions with patients and families regarding aducanumab in Alzheimer Disease, with recommendations for consent","volume":"98","author":"Chiong","year":"2022","journal-title":"Neurology"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007871?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378722007871?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:45:31Z","timestamp":1758519931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378722007871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0035378722007871"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.08.002","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}